

## Special Issue

# Health Technology Assessment (HTA) of New vaccines and New Target Groups and Impact Evaluation and Effectiveness of Current Vaccination Strategies

### Message from the Guest Editors

Dear colleagues,

In the current global health scenario, there is a strong need for evidence-based choices to rationalize the use of limited available resources and maximize results in terms of health, especially for prevention activities.

The aim of the Special issue is to collect HTA studies on vaccination that can provide careful and indepth analysis of both epidemiological/clinical data and organization vaccination practices, also including the economic evaluations of new vaccines (such as RSV and SARS-CoV-2) or new vaccination strategies. We hope research articles on the impact of vaccination programs analyzing the reduction of notifications, hospitalizations, or deaths due to vaccine-preventable diseases (measles, rubella, varicella, et al.) would be appreciated. Monitoring studies of vaccination coverage trends over time and seroepidemiological studies are also welcome.

The final objective is to give voice to all vaccination practices that, at an acceptable and sustainable cost, can improve the quality of life of all people.

---

### Guest Editors

Prof. Dr. Paolo Bonanni

Dr. Angela Bechini

Dr. Sara Boccalini

---

### Deadline for manuscript submissions

closed (31 December 2021)



## Vaccines

---

an Open Access Journal  
by MDPI

---

**Impact Factor 3.4**  
**CiteScore 9.9**  
**Indexed in PubMed**



[mdpi.com/si/67999](https://mdpi.com/si/67999)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).